| Name | Title | Contact Details |
|---|---|---|
Anju Chatterji |
Chief Technical Officer | Profile |
Revolutionizing life sciences procurement. AI-powered digital marketplace for complete transparency into your supply chain Labviva integrates with your existing purchasing software to provide you with actionable insights to make better decisions. Keep your current suppliers, contract pricing, and your purchasing software and processes. Our digital marketplace offers unparalleled visibility into your procurement process, to empower informed decisions to drive science forward without interruptions to your research.
Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Taiga Biotechnologies is a privately-held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions.